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Abstract
Highly sensitive methods for the assessment of clot structure can aid in our understanding of
coagulation disorders and their risk factors. Rapid and simple clot diagnostic systems are also
needed for directing treatment in a broad spectrum of cardiovascular diseases. Here we
demonstrate a method for micro-elastometry, named Resonant Acoustic Spectroscopy with
Optical Vibrometry (RASOV), which measures the clot elastic modulus (CEM) from the intrinsic
resonant frequency of a clot inside a microwell. We observed a high correlation between the CEM
of human blood measured by RASOV and a commercial Thromboelastograph (TEG), (R=0.966).
Unlike TEG, RASOV requires only 150 μL of sample and offers improved repeatability. Since
CEM is known to primarily depend upon fibrin content and network structure, we investigated the
CEM of purified clots formed with varying amounts of fibrinogen and thrombin. We found that
RASOV was sensitive to changes of fibrinogen content (0.5–6 mg/mL), as well as to the amount
of fibrinogen converted to fibrin during clot formation. We then simulated plasma
hypercoagulability via hyperfibrinogenemia by spiking whole blood to 150% and 200% of normal
fibrinogen levels, and subsequently found that RASOV could detect hyperfibrinogenemia-induced
changes in CEM and distinguish these conditions from normal blood.
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Blood coagulation is a vital physiological process for preventing hemorrhage via formation
of an insoluble clot. However, inappropriate coagulation can lead to intravascular
thrombosis and occlusion of blood flow; this presentation is responsible for most
cardiovascular disease-related deaths and complicates many pathological conditions.
Abnormal mechanical properties of clots are associated with the risk of thrombosis and the
response to clinical treatments, including angioplasty and thrombolytic therapy.
Demonstrated correlations between abnormally high clot stiffness and disease, including
myocardial infarction at a young age8 and diabetes in patients with chest pain,3 also
highlight the clinical significance of the clot elastic modulus (CEM).
Although the elastic modulus of individual fibers within a fibrin clot have successfully been
measured by instruments such as optical tweezers,6 reliable and repeatable clinical tools for
elastometry of blood clot samples are still lacking. Thromboelastography (TEG) has been
widely used in a clinical setting for monitoring coagulation during procedures including
hepatic and cardiac surgeries, which are associated with high risk of massive bleeding.12
However, TEG is not an ideal modality for assessing clot mechanical properties due to its
poor sensitivity, repeatability, and lack of standardization.23 While the poor standardization
of TEG may be due to the absence of standard clinical protocols, it may also be related to
the physical method of measurement which requires accurate measurement of stress and
strain, involves applying high strains to the clots that induce nonlinearity, and depends upon
binding of the clot fibers to the apparatus surfaces.
Recently we developed a new method for elastometry called resonant acoustic spectroscopy
with optical vibrometry (RASOV) which offers several advantages over traditional stress-
strain elastometry including high measurement sensitivity and small sample volume.16,18,27
In RASOV, the elastic modulus can be directly computed from the intrinsic resonant
frequency of a sample in a well-defined geometry. Clot samples are vibrated via a
downward pointing magnetic force applied to a microbead that rests on the sample surface,
and the use of small strains ensures that samples remain within the linear viscoelastic
regime. Samples are vibrated using a frequency sweep to detect the fundamental resonant
frequency of the sample. Displacement is recorded by optical interferometry with high
sensitivity (~6 nm) and speed (~ 2 second scan time). The fundamental resonant frequency
is then obtained by fitting the peak in the acoustic spectrum.16 This resonance technique
offers high signal-to-noise resulting in high precision elastometry. RASOV was first
demonstrated on agarose gel cylinders with open boundaries where gel elastic modulus was
computed according to a model solution.16 Thereafter, RASOV was employed to study
fibrin clots formed inside rigid microwells where the clot resonant frequency was shown to
be increasing with fibrinogen content.18 However, exact computation of elastic modulus in
the microwells has thus far been elusive due to the lack of accurate models for the closed-
wall boundary condition and shifts in resonant frequency observed when using actuators
with various masses.27
In this work we report for the first time, RASOV-based measurements of the CEM of human
blood and calibration of CEM using a commercial texture analyzer as a standard. We also
compare the performance of RASOV against TEG in matched human blood samples and
show quantitatively how the CEM of fibrin clot samples varies with fibrinogen and thrombin
concentration. Finally, we apply RASOV to measure CEM in human blood clots formed
with added fibrinogen to simulate a state of hypercoagulability. This constitutes a significant
advance toward the characterization and standardization of RASOV for clinical blood CEM
measurement.
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The main components of the RASOV system are an optical displacement sensor, a low
inertia mechanical actuator, and a microwell to provide defined boundary conditions for the
blood clot (Figure 1A). Plastic microwells were produced by 3D stereolithography printing
and are rectangular with dimensions of 5 mm (l) × 5 mm (w) × 6 mm (h) requiring a blood
volume of only 150 μL for testing.
Nanoscale displacement sensing was performed by a spectral-domain optical coherence
tomography (SD-OCT) system, previously described in detail,17 which has the advantage of
providing B-mode imaging of the micro-actuator placement on the clot samples.18,27 We
note that it is also feasible to construct a RASOV with a simpler, single point optical
vibrometer. Briefly, the SD-OCT system provides a broadband 800nm laser beam focused
onto the center of a chrome steel microbead (grade 25, 0.5 mm diameter, Salem ball
company) gently placed on top of the clot sample using tweezers. The microbead acts as a
mechanical actuator, has low inertia (~0.7 mg mass) so as to minimize the perturbation on
the native resonance of the clot, and provides a high reflectivity surface for motion tracking
by OCT. An example B-mode (x-z) OCT image of a blood clot is shown in Figure 1B. For
rapid displacement sensing, the OCT interferogram was recorded in M-mode (z versus time
t while transverse position x was fixed) during mechanical excitation. The phase angle of the
complex-analytic OCT signal was unwrapped in time to obtain the optical phase φ(z,t). The
displacement Δz was obtained from the optical path delay according to Δz (z, t) = φ(z, t) ·
λ/4π, where λ is the wavelength. The displacement resolution (i.e., the standard deviation
of a stationary object) was found to be ~6 nm at a 2 kHz sampling rate for this system, as
limited by the phase noise inherent to the OCT system. The acoustic spectrum was then
computed by Ĩ (z,ω)=F (Δz (z, t))/ F (F (t)) for a linear, time-invariant system where F(t) is
the driving force waveform comprised of a frequency-swept sinusoid and F is the Fourier
transform.16 Ĩ(z, ω) is subsequently averaged in z for pixels above a minimum threshold
intensity. The amplitude and phase of the acoustic spectra were then computed (e.g., Figs.
2C and 2D, respectively). The acoustic phase spectrum represents the phase difference
between the sample motion, Ĩ(ω), and the driving force, F(ω), which undergoes a
characteristic shift from 0 to π at resonance.
The driving force F(t) acting on the microbead actuator was supplied by a water-jacketed,
solenoid electromagnet with a linearly increasing frequency (chirped frequency) spanning
0–200 Hz, 0–400 Hz and 0–1 kHz, and sampled at linerates of 1 kHz, 2 kHz, and 5 kHz,
respectively, where the scan displaying the best fundamental resonance signal was chosen
for subsequent analysis. (Example frequency versus time and resultant displacement
waveforms are shown in Figs. 2A and 2B, respectively). We find that these frequency ranges
appropriately cover the fundamental resonant frequencies of our samples. Slow drift (a
downward slope in the displacement plot of Fig. 2B) is apparent but has little effect on the
resulting acoustic spectrum. To ensure the clot samples remained in the linear viscoelastic
regime, the peak-to-peak displacement was typically < 300 nm corresponding to a maximum
strain and strain rate of 5 × 10−5 and 0.05 s−1, respectively.
To compute sample elastic modulus (also known as Young’s modulus), we measured the
resonant frequency f0 from a least-squares fitting of the acoustic spectrum to a linear
viscoelastic model which has the solution of a complex Lorentzian, as previously.16 An
example of the fitting for a blood clot is shown in Figures 2C and 2D. Assuming a
homogeneous and elastically isotropic sample, we used:
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where E is the CEM, ρ is mass density, and a0 is a constant that depends upon Poisson’s
ratio, the sample geometry, and boundary conditions.16 While the RASOV microwell
controls the geometry and boundary condition of the sample, the Poisson’s ratio for blood
clots has been shown to be constant in low strain conditions (and close to that of water).2
For this study, we set ρ for blood to a value of 1060 g/L,11 while recognizing that intra- and
inter-individual variability is on the order of ~5 g/L.10 As ρ of gels and purified fibrin clots
is expected to deviate from that of water in these experiments by <0.1%, ρ was set to equal
to the density of water for measurements of gels and purified fibrin clots. We then calibrated
RASOV as detailed below by determining the characteristic a0 value for our microwell using
controlled gels with similar mechanical properties as blood clots. Using inexpensive agarose
gels allowed us to prepare larger samples needed to gain sufficient accuracy with the
commercial mechanical analyzer.
RASOV Calibration
Agarose gel was chosen for calibration because its density and Poisson’s ratio are close to
that of water. In addition, the elastic modulus of the agarose gel can be easily manipulated
by changing the agarose concentration. Aqueous gels with 3–10 mg/mL agarose (Type I-A,
Low EEO, Sigma) were prepared into the microwell for RASOV measurements and into 62
mm diameter and 38 mm height cylindrical dishes for texture analyzer measurements. Gels
were sealed and refrigerated for 12 hours (4 °C before being warmed to room temperature
for 60 mins at which point the seals were removed and measurements obtained.
To calibrate the elastic moduli of the gel samples, a texture analyzer (TA.XT Plus, Texture
technologies) was used. The texture analyzer was used in quasi-static compression with a
flat plate probe while measuring the reaction force from the sample. Compression was
performed at 0.5 mm/s up to 2% engineering strain where gels remained in the linear elastic
regime. The elastic modulus was calculated from the ratio of the true stress to true strain
over a range of 0.1%–1.7% strain. Three samples were prepared at each concentration and
measurements were repeated on separate days. The average elastic modulus at each
concentration is plotted in Figure 3A. Resonant frequencies were subsequently measured on
concentration-matched gels using RASOV, where quality factors typically between 2 and 5
were observed. This frequency data is shown in Figure 3B.
The concentration-dependent elastic modulus of agarose was observed to follow a
phenomenological power-law model with a power of 2, similar to previously reported
results1,16. Thus, we performed a weighted least-squares fit to the texture analyzer data
according to E=a1(c−c0)2, where c is the agarose concentration. At the same time, the
fundamental resonant frequency f0 measured by RASOV was found to be linearly
proportional to c. We therefore performed a weighted least-squares fit to the RASOV data
according to f0 =a2(c−c0), where a1 and a2 are constants of proportionality and c0 effectively
corresponds to the threshold concentration below which agarose will not gel. Note that these
equations are collectively consistent with the elastic theory equation E = a0ρ f02 if a0 = a1/
(a22ρ), lending credence to our observation of the linearity of f0 with c. We first fit the
RASOV data to find the values of a2 and c0, and then we fit the texture analyzer data using
the c0 value to find the value of a1. Using the agarose sample density ρ as that of water, a0
was then calibrated and used with E = a0ρf02 to compute E for any material with the same
Poisson’s ratio measured in a microwell with the same geometry. As shown in Fig. 3, we
measured a0 = (7.6 ± 0.3)×10−5 m2 over the range from 4–60 kPa using the agarose gels.
This a0 value was then used to compute CEM for all subsequent clot samples.
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Human alpha-thrombin was from Haematologic Technologies Inc. Purified human
fibrinogen (depleted of plasminogen, fibronectin, and von Willebrand factor) was from
Enzyme Research Laboratories. Bovine serum albumin (BSA) was from Fisher Scientific.
Innovin (tissue factor, TF) from Dade Behring was diluted 1/30000 for use in clotting
experiments.
Clot Preparation
Three types of clot samples were investigated. First, purified fibrin clot samples with
varying fibrinogen and thrombin content were prepared to investigate the sensitivity of
RASOV to concentration changes of these blood constituents. Second, blood samples
collected from 4 healthy volunteers were used to compare CEM measured by RASOV and
TEG. Third, simulated hyperfibrinogenemic blood clot samples were prepared from blood
collected from 3 healthy volunteers for measurement by RASOV.
For purified clot samples, the sample buffer was made by combining 20 mM N-2-
hydroxyethylpiperazine-N′-2-ethanesulfonic acid (pH 7.4), 150 mM NaCl (HBS) with 1
mg/mL bovine serum albumin, and 5 mM CaCl2. Human purified fibrinogen (0.5 – 6 mg/
mL final) was thawed at 37 °C and vigorously mixed by pipetting with the buffer and human
alpha-thrombin (5 or 20 nM final) into the RASOV microwells (150 μL) at room
temperature. Samples were sealed inside a humidified container immediately after mixing
and were measured between 3 and 4 hours after clotting to ensure the clot was fully
solidified.
Whole blood was collected via venipuncture into evacuated tubes containing 0.105 M/3.2%
sodium citrate (pH 6.5), according to a protocol approved by the University of North
Carolina Institutional Review Board. Coagulation was triggered in freshly-collected blood
within 15 minutes of the blood draw. For RASOV measurements, each microwell was
loaded with 142 μL blood mixed with 8 μL TF solution by pipetting.
Simulated hyperfibrinogenemic blood clots were made by spiking whole blood with human
purified fibrinogen to 4.5 and 6 mg/mL (quantities that mimic a final percentage of 150%
and 200% of normal, respectively). The fibrinogen concentration in human normal pooled
plasma was previously measured to be 3 mg/mL by enzyme-linked immunosorbent assay.13
Fibrinogen-spiked blood (142 μL) was mixed with 8 μL TF solution for each RASOV
microwell (87.2% whole blood, final) by pipetting. Both normal and fibrinogen-spiked
blood clot samples were sealed inside a humidified container immediately after mixing and
measured within 2 hours. This shorter time (2 hours) than that used for the purified samples
(4 hours) was chosen to better match that of the TEG measurements (~1 hour).
Thromboelastography Assay
Thromboelastography (TEG) was performed according to the manufacturer’s instructions
(Model 5000, Haemoscope Corp.), as follows: 340 μL of citrated blood was vigorously
mixed with 20 μL TF solution in the reaction cup by pipetting. TEG measurements were
performed at 37 °C within 15 minutes after phlebotomy. The shear modulus, G, of each
blood clot sample was calculated in Kdyn/cm2 using the equation in the product manual: G
= 5·MA/(100 − MA), where MA is the maximum amplitude of the TEG graph in mm (i.e.,
the maximum induced pin movement in response to oscillation of the cup). Under the
assumption that the blood clot formed inside the cup is homogenous and isotropic, the blood
CEM was obtained from G according to E=2G(1+ν), where ν is Poisson’s ratio. We set ν =
0.5 based on previous measurements of blood clots at small strains2 and therefore calculated
E using E = 15·MA/(100 − MA).
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Comparison between RASOV and TEG of Whole Blood
First, we calibrated the resonant frequency obtained by RASOV with the elastic modulus of
the sample using a commercial texture analyzer as a standard. The concentration-dependent
resonant frequency of agarose gel measured by RASOV was highly linear (R2 = 0.9954),
and when combined with texture analyzer measurements of the same gels, is consistent with
a phenomenological power-law model relating elastic modulus to the square of agarose
concentration.1,5,16 Overall, calibration of the RASOV instrument constant a0 of Eq. 1 was
possible with only 4% uncertainty over the range from 4–60 kPa. We note that this
calibration curve is expected to be valid for any resonant acoustic measurement that employs
a microwell of the same dimensions and a micro-actuator of the same mass.
Next, to compare the performance of RASOV with a commercially-available clot
mechanical analyzer, human whole blood clot CEM was measured by both RASOV and
TEG. Four healthy individuals were enrolled in this study and blood was obtained from two
of the donors on two separate days for a total of six blood samples. Four samples of each
blood draw were measured by RASOV and TEG (Figure 4) showing a high correlation (R =
0.966) over the range of CEM from ~1.5–5kPa. Interestingly, while the slope (0.83 ± 0.12)
of the fitting line was less than 1, the RASOV measurements are typically larger than TEG
except at very high CEM (>5 kPa). Additionally, we found that the CEM for blood from
subject B changed considerably between different days, an effect which was detected by
both RASOV and TEG. Importantly, the intra-sample variability of RASOV was only 0.17
± 0.05 kPa in comparison to 0.3 ± 0.1 kPa for TEG. We also explored the discrepancy
between TEG and RASOV measurements using a Bland-Altman plot to investigate the
possible relationship between the measurement difference and mean CEM value. While the
discrepancy between the two measurements was not statistically significant (p-value=0.25
by a paired t-test), there is no strong evidence showing that a larger difference appears at
greater values of CEM.
CEM of Purified Fibrin Clots
During clot formation, fibrinogen chains are cleaved by thrombin converting fibrinogen to
fibrin monomer. Fibrin monomers are then polymerized into a network of fibrin that
comprises the main structural component of a blood clot.25 In our study, purified fibrin clots
with various fibrinogen and thrombin concentrations were prepared to study the sensitivity
of RASOV for detecting clot structural changes. Fibrinogen concentrations (0.5–6 mg/mL)
were chosen to range across hypofibrinogenemia, normal blood, and hyperfibrinogenemia.
Four fibrin clot samples were prepared and measured by RASOV at each fibrinogen and
thrombin concentration and repeated on a different day. The quality factor for the
fundamental resonances of the fibrin clots was typically found to be between 2 and 3. The
mean and standard deviation of the CEM that were obtained are shown in Figure 5A. TEM
images of clots formed from 1.2 mg/mL and 3.2 mg/mL fibrinogen (20 nM thrombin, final)
confirmed that the fibrin fibers were homogeneously distributed inside the clot and
increased fibrinogen content resulted in an increased fiber density (Figure 5C and D).
As expected, CEM increased with increasing fibrinogen content exhibiting an apparent
power-law dependence at 20 nM thrombin (Figure 5A). Interestingly, at high fibrinogen
concentrations (5 and 6 mg/mL), the CEM was lower for clots with 5 nM thrombin
compared to clots with 20 nM thrombin, where the 5 nM curve appeared to level off at the
high fibrinogen concentrations. We hypothesized that these effects were due to incomplete
conversion of fibrinogen into fibrin fibers. To test this hypothesis we performed SDS-PAGE
on supernatant taken from clots prepared with 5 and 6 mg/mL fibrinogen final, each at 5 and
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20 nM thrombin final. Contents of the supernatants included material not incorporated into
the fibrin gel. Figure 5B shows a loading control band in every condition corresponding to
BSA protein present in the buffer. The three bands underneath the BSA line show the Aα,
Bβ, and γ chains of the fibrinogen protein, respectively, and indicate the presence of free
(unclotted) fibrinogen in the sample supernatant. These bands were present in clots produced
by 5 nM thrombin incubated with 5 and 6 mg/mL fibrinogen, but not in clots produced by
20 nM thrombin. This result is consistent with the theory that thrombin is trapped in the
fibrin network during the conversion of fibrinogen to fibrin, resulting in an insufficient
quantity of active remaining thrombin.22,25 Thus, at sufficiently low thrombin concentration
and sufficiently high fibrinogen concentration, active thrombin will be “sequestered,”
leaving some fibrinogen un-converted. This scenario would result in incomplete conversion
of fibrinogen to fibrin, even in a closed sample, and may explain the reduction in CEM
observed in clots produced with low thrombin and high fibrinogen concentrations. Indeed,
CEM is expected to be dictated by the amount of fibrin in the structural clot network, which
highlights the sensitivity of RASOV specifically to fibrin rather than free fibrinogen.
For clot samples with 20 nM thrombin where no free fibrinogen was detected, CEM
displayed a power law dependence on fibrinogen concentration with an exponent of 2.00 ±
0.09, which agreed with several models and measurements on clot mechanical behavior as
discussed in detail below.14,15,24
Hyperfibrinogenemic Blood
The ability to directly measure CEM in whole blood samples could have several advantages,
including minimal sample manipulation and rapid characterization of CEM in patients at
risk for thromboembolic disease. Thus, a direct test was performed to assess the ability of
RASOV to measure CEM of human whole blood clots both with and without additional
fibrinogen to simulate a state of hyperfibrinogenemia. Blood from 3 healthy subjects was
either measured directly or spiked with purified human fibrinogen to levels that were 150%
and 200% of normal, while each condition was split into two wells for measurement by
RASOV (Figure 6). The CEM responses were statistically different in 3 groups of blood
types (p-value<0.001). The fibrinogen-spiked blood samples exhibited significantly higher
mean CEM (p-value=0.007 for 150% fibrinogen spiked and p-value<0.001 for 200%
fibrinogen spiked) than normal blood.
Discussion
Comparison Between Clot Elastometry Methods
First developed in 1948, TEG has gained wide clinical acceptance and has become a gold
standard for monitoring blood coagulation. However, its use in a clinical coagulation
laboratory has been limited by poor repeatability and lack of standardization.12,23 The
current method of TEG involves incubating freshly drawn blood in a 360 μL cup with a pin
at the center. The TEG cup is oscillated at a fixed angle of 4.75° during blood coagulation,
which defines the shear strain. The cup motion is increasingly transmitted by the forming
blood clot to the center pin, where the maximum amplitude (MA) of the pin motion is
recorded when the blood clot is stabilized. MA is directly related to the sample stress, which
can then be used with the known strain to compute the shear modulus and subsequently the
CEM. Thus, TEG requires high accuracy in both stress and strain to obtain an accurate
measurement of CEM. Interestingly, due to the nonlinear relationship between CEM and
MA, TEG is less sensitive to CEM when the clot has a higher CEM.
In contrast to TEG, RASOV is not yet capable of measuring dynamic changes such as
clotting time during blood coagulation. However, RASOV offers several advantages over
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TEG: 1) Smaller sample volumes (150 μL vs. 360 μL) may enable longitudinal studies on
small animals. 2) Smaller strains may avoid nonlinearity in the stress-strain curve which
may result in better accuracy to CEM. 3) The ability to rapidly repeat measurements on a
single sample provides better statistics. 4) Greater repeatability in CEM was found when
comparing multiple samples from the same blood draw. (The standard deviation was 0.17
kPa for RASOV compared to that of 0.30 kPa for TEG). These features make RASOV an
attractive developing technology for measuring blood clot properties.
It is important to recognize possible sources of systematic error in RASOV, which mainly
arise from three sources: calibration, inter-individual variability of blood density, and
changes in sample geometry. With respect to calibration, there is 4% uncertainty by fitting
the calibration data to our model over a span from 4–60 kPa. It is important to note that the
minimum elastic modulus possible to calibrate using agarose was 4 kPa, compared to a
minimum of 1.7 kPa for blood clots. Thus, the confidence of RASOV measurements below
4 kPa arises from extrapolation of the agarose data, which is linear in a range spanning over
an order of magnitude, as well as the consistency of the purified clot results below 4 kPa
with prevailing models. In terms of variability, each individual’s blood may have a different
mass density, which we expect will contribute on the order of 0.5% variability to CEM
measurements.10 Finally, the sample clot slowly loses volume due to dehydration during
analysis, which can shift the resonant frequency. Our comparison study between RASOV
and TEG showed that, while the techniques were highly correlated (R=0.966), RASOV
offered significantly better precision (by nearly half). It is important to note that TEG
depends on the ability of the clot fibers to attach to the cup and pin during excitation. As a
result, the CEM measured by TEG could be lower than the actual value if not all fibers
transfer stress from the cup to the center pin or if some fibers break in the middle of the
measurement. We suggest that this feature is one of the major reasons why RASOV
generally exhibited a higher measurement value than TEG in matched samples. Future
hardware improvements will include extending RASOV to provide data during coagulation
such as the clotting and lysis time. We also expect that enclosing the system in a
temperature- and humidity-controlled chamber will further reduce systematic error.
CEM of Purified Clots
At low strains, elastic modulus and protein concentration are expected to have a power law
relationship. A current model for semiflexible biopolymers predicts the exponent to be
approximately 2.5 for densely cross-linked gels and 2.2 for physically entangled gels.14
Several attempts were previously made to measure the fibrin concentration dependence
experimentally. Weigandt, et al measured this exponent to be 2.22 using rheology,24 while
Nelb, et al showed a measured exponent of 1.9 for fine, unligated human fibrin clots using
the Plazek apparatus.15 In RASOV, the power law exponent was least-squares fitted to be
2.00 ± 0.09, which is consistent with these previous measurements. Importantly, this shows
that the performance of RASOV is comparable to more conventional, non-clinical rheology
techniques.
Importantly, we detected free fibrinogen in fibrin clots with low thrombin content (5 nM
final) and high fibrinogen content (5 and 6 mg/mL), suggesting that thrombin did not
successfully convert all fibrinogen to fibrin. This experimental observation is consistent with
the premise that fibrin(ogen) has “antithrombin” properties, whereby thrombin bound to
fibrin becomes sequestered within the fibrin network during clot formation, and therefore,
functionally inhibited.26 The fact that RASOV detected lower CEM in these samples
highlights its sensitivity to the polymerized fibrin contained within the network as opposed
to free (unincorporated) fibrinogen. Future studies with RASOV may enable the
establishment of quantitative relationships between clot composition and CEM.
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CEM of Fibrinogen-Spiked Whole Blood Clots
Elevated fibrinogen is associated with increased risk of certain cardiovascular diseases.4,21
Results from previous studies may suggest that this association stems from fibrinogen
concentration-dependent effects on the resulting blood clot structure (greater fiber and
branchpoint densities).13,19,25 Here we apply RASOV for the first time to quantify the
effects of added fibrinogen on CEM in human whole blood clots. Our data indicate that the
CEM of fibrinogen-spiked blood increased significantly in conditions of simulated
hyperfibrinogenemia, consistent with previous studies.7 The lower sample volumes and high
repeatability of RASOV provides a new platform to study hyperfibrinogenemia and to foster
insight into the pathologic role of blood hypercoagulability in many diseases, including
juvenile idiopathic arthritis,9 myocardial infarction,20 and coronary heart disease.21
Conclusion
In summary, we have developed novel, high-sensitivity micro-elastometry via resonant
acoustic spectroscopy (RASOV) that measures blood clot elastic modulus. Our results
indicate that CEM is strongly influenced by fibrinogen concentration and may provide
important information on the mechanistic role of fibrinogen and other coagulation proteins
in blood clot functionality. RASOV can also be employed to study the effects of other blood
components and functions such as red blood cells and platelet contractile force, which have
been shown to contribute to clot stiffness.4 In the future, a portable RASOV instrument with
multiple sample inputs could greatly reduce the measurement time and cost per sample in
clinical application. With utility for both fundamental animal model research and clinical
medicine, RASOV has the potential to promote understanding of the relationships between a
clot’s structure, composition, and its functional mechanical properties, and may provide
critical diagnostic data for post-surgical monitoring and in patients undergoing prophylactic
hemostatic and antithrombotic treatment regimens.
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(a) Schematic diagram of RASOV integrated with an optical coherence tomography (OCT)
system. The electromagnet used in conjunction with the microbead provides a modulated,
frequency-swept force on the clot sample. The sample response (bead displacement) is
captured by the OCT system to measure the resonant frequency of the sample. (b) Cross-
sectional OCT image of a whole blood clot with a microbead placed at the center. While the
blood clot surface is not visible underneath the microbead due to its high optical attenuation,
it was found that the surface locally deforms to accommodate the weight (~0.7 mg) of the
microbead.
Wu et al. Page 11














An example of signal processing on RASOV data from a whole blood clot. (a) Timing of the
frequency sweep of the driving force (0–400 Hz) generated by the magnet. (b)
Corresponding measurement of average bead displacement showing increased vibration
amplitude at the time when the driving frequency nears 206 Hz (Q≈2.2). (c) Computed
acoustic vibration amplitude spectrum and fitting to a linear viscoelastic model, displaying a
peak at 206 Hz. (d) Computed acoustic phase spectrum and model fitting. The phase
exhibits a telltale shift from 0 to π at the resonance according to the Lorentzian solution to
the linear viscoelastic model.
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RASOV calibration using agarose gels of varying concentration. (a) Elastic modulus
measured using a texture analyzer. (b) Resonant frequency measured using RASOV. Model
fitting provides the proportionality constant characteristic of our RASOV system. In this
way, a RASOV measurement of f0 provides the CEM of an unknown sample.
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CEM of human blood measured by RASOV and TEG. Blood from two of the four donors
(Subjects A and B) was measured twice on different days to highlight the intra-individual
variability. Error bars indicate standard deviation over 4 identical samples.
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Properties of purified fibrin clots with varying fibrinogen and thrombin content. (a) CEM
measured by RASOV exhibits a power-law dependence at 20 nM thrombin, but a reduction
of CEM at 5 nM thrombin when the fibrinogen content is high. (b) SDS-PAGE showing: 1.
Sample buffer as negative control (20 nM HBS, 5 mM Ca and 1 mg/mL BSA). 2. Sample
buffer with 1 mg/mL purified fibrinogen as positive control. 3. Unclotted supernatant from
low fibrinogen, low thrombin clot (5 mg/mL fibrinogen and 5 nM thrombin). 4. Unclotted
supernatant from high fibrinogen, low thrombin clot (6 mg/mL fibrinogen and 5 nM
thrombin). 5. Unclotted supernatant from low fibrinogen, high thrombin clot (5 mg/mL
fibrinogen and 20 nM thrombin). 6. Unclotted supernatant from high fibrinogen, high
thrombin clot (6 mg/mL fibrinogen and 20 nM thrombin). (c) and (d) TEM images
corresponding to fibrinogen levels of 1.2 mg/mL and 3.2 mg/mL (with 20 nM thrombin)
show that fiber density increases with fibrinogen concentration.
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CEM of blood with varying elevated fibrinogen levels as measured by RASOV.
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